219 related articles for article (PubMed ID: 23622710)
1. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.
Spratt DE; Scala LM; Folkert M; Voros L; Cohen GN; Happersett L; Katsoulakis E; Zelefsky MJ; Kollmeier MA; Yamada Y
Brachytherapy; 2013; 12(5):428-33. PubMed ID: 23622710
[TBL] [Abstract][Full Text] [Related]
2. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
3. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
4. Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer.
Chatzikonstantinou G; Keller C; Scherf C; Bathen B; Köhn J; Tselis N
Brachytherapy; 2021; 20(1):44-49. PubMed ID: 32826171
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
7. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.
Fröhlich G; Agoston P; Lövey J; Somogyi A; Fodor J; Polgár C; Major T
Strahlenther Onkol; 2010 Jul; 186(7):388-95. PubMed ID: 20582396
[TBL] [Abstract][Full Text] [Related]
9. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
10. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
[TBL] [Abstract][Full Text] [Related]
11. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment.
Kamrava M; Chung MP; Kayode O; Wang J; Marks L; Kupelian P; Steinberg M; Park SJ; Demanes DJ
Brachytherapy; 2013; 12(5):434-41. PubMed ID: 23406987
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
13. Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.
Lakosi F; Antal G; Vandulek C; Kovacs A; Toller GL; Rakasz I; Bajzik G; Hadjiev J; Bogner P; Repa I
Pathol Oncol Res; 2011 Jun; 17(2):315-24. PubMed ID: 21221879
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy.
Nicolae A; Murgic J; Kruljac I; Dubnitzky L; D'Alimonte L; Lu L; Cumal A; Law N; Morton G; Loblaw A; Chung HT; Ravi A
Brachytherapy; 2018; 17(2):306-312. PubMed ID: 29239812
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
16. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
17. Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.
Fuller DB; Naitoh J; Mardirossian G
Front Oncol; 2014; 4():321. PubMed ID: 25505732
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer.
Cengiz M; Dogan A; Ozyigit G; Erturk E; Yildiz F; Selek U; Ulger S; Colak F; Zorlu F
Brachytherapy; 2012; 11(2):125-9. PubMed ID: 22192496
[TBL] [Abstract][Full Text] [Related]
19. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
20. Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].
Zaorsky NG; Hurwitz MD; Dicker AP; Showalter TN; Den RB
Expert Rev Med Devices; 2015 May; 12(3):317-27. PubMed ID: 25540018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]